Metabolically engineered E. coli produces xanthohumol and desmethylxanthohumol in bioreactors, indicating potential for sustainable bioactive compound production.
Xanthohumol is a prenylflavonoid from hops with relevant bioactivities. Microbial production has emerged as a sustainable and potentially economic solution to produce it. Herein, we constructed a pathway for the de novo production of xanthohumol in Escherichia coli. Since the xanthohumol pathway depends on the availability of dimethylallyl pyrophosphate (DMAPP) and S-adenosylmethionine (SAM), SAM synthase (metK) was integrated into the genome of E. coli strains with previously engineered DMAPP pathways. Eleven prenyltransferases (PT) and the O-methyltransferase (OMT) from Humulus lupulus (HlOMT1) were tested. E. coli M-PAR-121:BlIDI:metK, constructed by integrating metK into the E. coli strain with integration of isopentenyl diphosphate isomerase (IDI) from Bacillus licheniformis (E. coli M-PAR-121:BlIDI) and expressing CdpC3PT from Neosartorya fischeri and HlOMT1 in combination with the naringenin chalcone pathway, was the best producer. This strain was able to produce 7.3 mg/L of desmethylxanthohumol and 5.3 mg/L of xanthohumol in the bioreactor, representing the first report of de novo production of xanthohumol in E. coli.
No takes yet. Share an insight, caveat, or question.
Gomes et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: